Vialon Magaly, Desailloud Rachel, Caron Philippe
Service endocrinologie et maladies métaboliques, pôle cardio-vasculaire et métabolique, CHU Larrey-Rangueil, Toulouse, France.
Service endocrinologie-diabète-nutrition, CHU Amiens, France.
Ann Endocrinol (Paris). 2019 Sep;80 Suppl 1:S19-S28. doi: 10.1016/S0003-4266(19)30113-1.
Multiple Endocrine Neoplasia Type 1 (NEM1) is related to mutations of the menin gene. It is an autosomal dominant disease. Its prevalence is about 1/30 000 with a hugh penetrance. There is no genotype-phenotype correlation. This hereditary syndrome is characterized by the presence of tumors of the endocrine system (parathyroid, endocrine pancreas, pituitary and adrenal gland). Other disorders have also been described (bronchial and thymic carcinoid tumor, breast cancer, skin lesions). Management must take into account the specificities of these pathologies in NEM1 compared to sporadic forms (young age at diagnosis, multiple lesions within the same gland, multi-focal disease). © 2019 Published by Elsevier Masson SAS. All rights reserved. Cet article fait partie du numéro supplément Les Must de l'Endocrinologie 2019 réalisé avec le soutien institutionnel de Ipsen-Pharma.
1型多发性内分泌腺瘤病(MEN1)与Menin基因的突变有关。它是一种常染色体显性疾病。其患病率约为1/30000,具有高度外显率。不存在基因型与表型的相关性。这种遗传性综合征的特征是存在内分泌系统肿瘤(甲状旁腺、内分泌胰腺、垂体和肾上腺)。也有其他病症的描述(支气管和胸腺类癌肿瘤、乳腺癌、皮肤病变)。与散发性形式相比,MEN1的治疗必须考虑这些病症的特殊性(诊断时年龄较轻、同一腺体出现多个病变、多灶性疾病)。©2019由爱思唯尔马松SAS出版。保留所有权利。本文是在益普生制药公司的机构支持下制作的2019年内分泌学特刊的一部分。